U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07054931) titled 'Combination Vaccination and Broadly Neutralising Antibody Therapy in HIV' on May 16.
Brief Summary: There is no cure for HIV infection. Antiretroviral therapy (ART) is widely available but requires daily, life-long intake. This can cause issues around side-effects, resistance, adherence and stigma. A new therapy, broadly neutralising antibodies, (bNAbs), may work as well as ART and may last longer - one dose can last six months. bNAbs appear to first target HIV viruses, then drive a protective immune response conferring long-term control, called the vaccinal effect. AbVax is a clinical trial to understand this effect and how to enhan...